TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03241173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
Study: NCT03523000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intrathecal infusion of normal saline at a rate of 0.5-1.0 ml/hr for approximately 14-18 hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Drug Delivery System (IDDS)
Description: 40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Intrathecal Drug Delivery System (IDDS)
Description: 40-mL IDDS containing a solution of fentanyl 50 mcg/mL with bupivacaine 30 mg/mL
Study: NCT00823342

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CLEVUDINE + TENOFOVIR PLACEBO
Description: 30 MG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLEVUDINE IN ASSOCIATION TENOFOVIR
Description: TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TENOFOVIR + CLEVUDINE PLACEBO
Description: TENOFOVIR 300 mg qd + CLEVUDINE Placebo
Study: NCT02687659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEMIS system
Description: Wearing TEMIS system over the day during one week
Study: NCT02503345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177 low dose
Description: ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177 mid dose
Description: ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177 high dose
Description: ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
Study: NCT03826576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: The multicomponent intervention will be consist of:~1. Training of the restaurant staff (waiters and cookers) about Mediterranean and Healthy Diet and food allergens,~2. Nutritional and food allergen analysis of the menu of the restaurant~3. Improvement of the menu to follow the Mediterranian diet standards (AMED criteria), the nutritional quality of the menu and the adaptations of the menu for food allergies and food intolerances~4. Marketing campaign about healthy and food allergen adapted menus in the restaurants
Study: NCT00745615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod tablets/capsules will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching to laquinimod will be administered as per the dose and schedule specified in the respective arms.
Study: NCT02869984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Study: NCT02378025

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Group
Description: A 10-week yoga course designed to treat pain.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Management Wellness Group
Description: A 10-week behavioral therapy course designed to treat pain.
Study: NCT01247181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone text message
Description: Weekly message with motivational content

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care provided at clinic
Study: NCT04291378

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Proton versus photon radiation therapy
Description: The intervention is proton radiation therapy versus photon radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton versus photon radiation therapy
Description: The intervention is proton radiation therapy versus photon radiation therapy
Study: NCT01807832

Intervention type: OTHER
Group type: OTHER
Intervention: capsaicin challenge
Study: NCT03241173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCAGN01949
Description: In Phase 1, participants will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, participants will receive INCAGN01949 administered IV at the recommended dose from Phase 1.
Study: NCT02469961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interscalene block
Description: Interscalene block is used for the main anesthetic for the case
Study: NCT04475939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered
Study: NCT03241173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
Study: NCT04475939

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered
Study: NCT04563260

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline injection
Description: Normal saline 2 mL, intravenous injection
Study: NCT03241173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
Study: NCT03891576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.

Intervention type: DRUG
Group type: OTHER
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niraparib
Description: Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
Study: NCT03133559

Intervention type: OTHER
Intervention: Observational
Description: We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.

Intervention type: OTHER
Intervention: Observational
Description: We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.

Intervention type: OTHER
Intervention: Observational
Description: We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
Study: NCT01050101

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No fiber
Description: The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.~Test meal consists of breakfast meals containing muffins and yogurt beverage/shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low GI high fiber viscous meal
Description: Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low GI high fiber non-viscous
Description: Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).~Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake.
Study: NCT02999971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circuit class therapy in water
Description: The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circuit class therapy on land
Description: The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
Study: NCT01005628

Intervention type: DRUG
Intervention: bortezomib
Description: Injection into a vein 1.3 mg/m2 twice a week for 21 days
Study: NCT04908436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg BAY94-8862 immediate release (IR) tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg BAY94-8862 immediate release (IR) tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg BAY94-8862 immediate release (IR) tablet, administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY94-8862)
Description: 10 mg BAY94-8862 immediate release (IR) tablet, administered orally
Study: NCT03591861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: * Children under 2 years will immediately start on a full calorie classical 3:1 ketogenic diet. The 3:1 ratio indicates that the diet contains 3 g of fat for every 1 g of protein + carbohydrate, which results in about 87% of calories coming from fat.~* Children 2 years or older will skip breakfast and lunch on the day of admission but start a full calorie 3:1 ketogenic diet at dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: -Standard of care
Study: NCT01550575

Intervention type: DEVICE
Intervention: Non Boston Scientific Systems
Description: Spinal cord stimulation, RF, IDS etc.

Intervention type: DEVICE
Intervention: Non Boston Scientific Systems
Description: Spinal cord stimulation, RF, IDS etc.

Intervention type: DEVICE
Intervention: Boston Scientific Systems
Description: Spinal cord stimulation, RF, IDS etc

Intervention type: DEVICE
Intervention: Boston Scientific Systems
Description: Spinal cord stimulation, RF, IDS etc
Study: NCT04796818

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging
Description: Undergo IVIM DWI
Study: NCT04145115

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04563260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron Injection [Aloxi]
Description: Palonosetron 1.5 mL (0.075 mg) + Normal saline 0.5 mL, intravenous injection
Study: NCT03241173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
Study: NCT00107107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramlintide acetate
Description: Syringe vial and Pen-cartridge
Study: NCT02616822

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol
Description: Used for trans-resveratrol substance 300 mg single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Used for placebo substance single dose
Study: NCT04021862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody
Description: Bermekimab 400 mg or 800 mg will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody
Description: Bermekimab 400 mg or 800 mg will be administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study: NCT03991377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye movement desensitization and reprocessing therapy
Description: EMDR is an integrative psychotherapy that uses standardized protocols and elements of cognitive-behavioral, interpersonal, and body-centered therapies, as well as dual stimulation (e.g., side-to-side eye movements).~The current standard protocol includes eight phases:~1. Patient history.~2. Patient preparation.~3. Patient assessment.~4. Memory desensitization.~5. Installing the positive cognition.~6. Body scan.~7. Closure.~8. Reevaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
Study: NCT00806780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: on table cholangiography
Description: x-ray imaging of common bile duct
Study: NCT04083222

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ISIS 757456-matching placebo solution administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 757456
Description: ISIS 757456 administered as SC injection.
Study: NCT00620204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: atorvastatin 40mg qd for 1 year
Study: NCT02565823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise bout
Description: Participants will exercise for 45min at 75% of VO2peak
Study: NCT03538873

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Study: NCT03734354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole , single/oral/with fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole , single/oral/with fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Brexpiprazole , single/oral/with fasting
Study: NCT00765635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drops intilation (Taponoto ® )
Description: four drops, unique doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: drops intilation (Otocerum®)
Description: four drops, unique doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: drops intilation (Placebo)
Description: Placebo
Study: NCT03279250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone Acetate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO